What question did this study set out to answer?

The study aims to identify latent BMI trajectories in drug-naïve first-episode schizophrenia patients treated with second-generation antipsychotics.

December 8, 2025SchizophreniaOpen Access

Trajectory analysis of BMI increase induced by second-generation antipsychotics in first-episode schizophrenia: a secondary analysis based on CNFEST****

View Full Paper

Ask AI

Bookmark

Authors

Secondary analysis reveals distinct BMI trajectories in FES patients treated with antipsychotics, suggesting early preventive interventions.

The study aims to identify latent BMI trajectories in drug-naïve first-episode schizophrenia patients treated with second-generation antipsychotics.
Secondary analysis of the Chinese First-Episode Schizophrenia Trial (CNFEST)
Included 361 drug-naïve FES patients treated with olanzapine, risperidone, or aripiprazole
BMI measured at 7 timepoints over 12 months
Latent class trajectory modeling (LCTM) used to identify BMI trajectories
Multinomial logistic regression applied to detect predictors of trajectory membership.
Identified four BMI trajectories: LBRI, MBGI, LBSI, and HBSI
Baseline BMI was the strongest predictor of the LBRI trajectory
Higher odds of LBRI for olanzapine compared to aripiprazole (OR = 20.4)
Shorter duration of untreated psychosis and lower education increased LBRI risk
Advocates for dynamic risk stratification and early preventive interventions.

Yin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Secondary analysis reveals distinct BMI trajectories in FES patients treated with antipsychotics, suggesting early preventive interventions.